Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Deal History & Licensing Activity
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is a large pharma headquartered in Japan. Over the past three years, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) has been involved in 4 licensing and acquisition transactions, with a primary focus on Gene Therapy (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Gene Therapy
Focus Area
Rare Disease
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| muscle disorder capsid | Astellas | Gene Therapy | Unknown | license | Apr 10, 2026 |
| muscle disorder capsid | Astellas | Gene Therapy | Unknown | license | Apr 9, 2026 |
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Pipeline Focus
Therapeutic areas and modalities where Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Strategic Signals
Key indicators of Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Licensing & Deal Activity
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) include Rare Disease (4 deals and trials), Oncology (1 deal and trial), and Other (1 deal and trial). In terms of modality, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) has shown particular interest in gene therapy, bispecific antibodies, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.